

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Bri Biosciences Limited
腾盛博药生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

**(1) RESIGNATION OF EXECUTIVE DIRECTOR;
(2) APPOINTMENT OF EXECUTIVE DIRECTOR;
(3) CHANGE IN COMPOSITION OF STRATEGY COMMITTEE; AND
(4) APPOINTMENTS OF HEAD OF CHINA R&D AND
GENERAL MANAGER, GREATER CHINA**

RESIGNATION OF EXECUTIVE DIRECTOR

The Board hereby announces that Mr. Yongqing Luo tendered his resignation letter to resign as an executive Director with effect from September 15, 2022.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board hereby announces that Dr. Ankang Li has been appointed as an executive Director with effect from September 30, 2022.

CHANGE IN COMPOSITION OF STRATEGY COMMITTEE

The Board hereby announces the following change in composition of the Strategy Committee with effect from September 30, 2022:

- (i) Following the appointment of Dr. Ankang Li as an executive Director, he has also been appointed as the chairman of the Strategy Committee;
- (ii) Dr. Taiyin Yang has also been appointed as a member of the Strategy Committee; and
- (iii) Dr. Zhi Hong has ceased to be the chairman of the Strategy Committee.

APPOINTMENTS OF HEAD OF CHINA R&D AND GENERAL MANAGER, GREATER CHINA

The Board hereby announces the appointments of Dr. Qing Zhu as the Head of China R&D of the Company with effect from October 1, 2022, and Mr. Rico Liang as the Senior Vice President and General Manager, Greater China of the Company with effect from September 16, 2022.

RESIGNATION OF EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Brie Biosciences Limited (the “**Company**”) hereby announces that Mr. Yongqing Luo (“**Mr. Luo**”) tendered his resignation letter to resign as an executive Director, the President and General Manager, Greater China of the Company, and the chief executive officer of TSB Therapeutics Ltd (Beijing) Co. Limited (an indirect non-wholly owned subsidiary of the Company) (“**TSB Therapeutics**”), all with effect from September 15, 2022, in order to pursue other opportunities.

Mr. Luo has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the shareholders of the Company (the “**Shareholders**”) or The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board would like to take this opportunity to express its sincere gratitude to Mr. Luo for his valuable contribution to the Company during his tenure of service.

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board hereby announces that Dr. Ankang Li (“**Dr. Li**”) has been appointed as an executive Director with effect from September 30, 2022 in addition to his existing positions in the Company. Following the appointment of Dr. Li as an executive Director, he has also been appointed as the chairman of the strategy committee of the Board (the “**Strategy Committee**”) with effect from September 30, 2022. In addition, Dr. Li has been appointed as the chief executive officer of TSB Therapeutics with effect from September 16, 2022.

The biographical details of Dr. Li are set out below:

Dr. Li, aged 44, has been appointed as an executive Director with such appointment to take effect from September 30, 2022 and as the chief executive officer of TSB Therapeutics with such appointment to take effect from September 16, 2022. He has been serving as the joint company secretary of the Company since April 8, 2021, and the chief financial and strategy officer of the Company since January 1, 2022, responsible for overseeing financial, accounting, legal, intellectual property, corporate development, procurement, investor relations and communication on matters of the Group. He was the chief financial officer of the Company from September 1, 2020 to December 31, 2021.

Dr. Li has more than ten years of experience in investment banking, business development, legal transaction and biomedical research. Prior to joining the Group, he was the chief financial officer of Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company listed on NASDAQ Stock Exchange in the United States (stock code: TERN), and he was responsible for overseeing financial operation from June 2019 to August 2020. He was an executive director within the corporate finance department division of Goldman Sachs, an investment bank, and he was responsible for providing financial advisory services from January 2018 to June 2019. He was a director of the business development department of MSD R&D (China) Co., Ltd., a China subsidiary of a global pharmaceutical company Merck Sharp & Dohme Corporation (“**MSD**”), and he was responsible for overseeing business development and licensing transactions of MSD Asia

Pacific Innovation Hub from September 2016 to December 2017. He was an associate of Ropes & Gray LLP, a global law firm, and he was responsible for providing legal advisory services in corporate transactions from August 2014 to September 2016. He was an associate of Davis Polk & Wardwell LLP, a global law firm, and he was responsible for providing legal advisory services in corporate transactions from September 2012 to August 2014. From September 2007 to September 2009, he was a research associate of Salk Institute for Biological Studies, a scientific research institute in the United States, conducting postdoctoral scientific research.

Dr. Li obtained his Bachelor of Science in Biochemistry from Fudan University in China in July 1999, a Master of Science in Biological Sciences from National University of Singapore in Singapore in October 2002, a Ph.D. in Biomedical Sciences from Baylor College of Medicine in the United States in June 2007 and a Juris Doctor degree from The University of Chicago Law School in the United States in June 2012. Dr. Li was also admitted to the New York Bar in January 2013 and was qualified as a Chartered Financial Analyst of the CFA Institute in August 2016.

Dr. Li will enter into a service contract with the Company for an initial term of three years commencing from September 30, 2022, which may be terminated by not less than one month's notice in writing in advance served by either Dr. Li or the Company. Dr. Li will hold office until the next annual general meeting of the Company at which he will be eligible for re-election. Thereafter, Dr. Li will be subject to retirement by rotation and re-election in accordance with the articles of association of the Company. Pursuant to the service contract, Dr. Li will not receive any additional director's fee or remuneration in his capacity as an executive Director as his remuneration was covered in his current employment agreement with the Company in his capacity as the joint company secretary and the chief financial and strategy officer of the Company with reference to his contributions, experience and relevant duties and responsibilities within the Company.

As at the date of this announcement, Dr. Li is interested or deemed to be interested in 5,703,500 shares of the Company (the "Shares") within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), representing approximately 0.79% of the issued share capital of the Company, including (i) his holding of 899,832 Shares, (ii) his entitlements to receive up to 4,479,668 Shares pursuant to the exercise of options granted to him under the pre-IPO share incentive plan adopted by the Company on October 30, 2018 and the post-IPO share option scheme adopted by the Company on June 22, 2021, subject to the vesting conditions; and (iii) his entitlement to 324,000 Shares underlying the restricted share units granted to him under the post-IPO share award scheme adopted by the Company on June 22, 2021, subject to the vesting conditions.

Save as disclosed above, as at the date of this announcement, Dr. Li (i) does not hold any other positions with the Company or any of its subsidiaries; (ii) does not hold, and has not held in the last three years, any other directorship in any other public companies the securities of which are listed on any securities market in Hong Kong or overseas; and (iii) has no relationship with any Directors, senior management, substantial shareholders or controlling shareholders of the Company.

Save as disclosed above, there is no other information in relation to the appointment of Dr. Li which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Rules Governing the Listing of Securities on the Stock Exchange, nor are there other matters in relation to the appointment of Dr. Li that need to be brought to the attention of the Shareholders.

The Board would like to express its warm welcome to Dr. Li for joining the Board.

CHANGE IN COMPOSITION OF STRATEGY COMMITTEE

The Board hereby announces that the following change in composition of the Strategy Committee with effect from September 30, 2022:

- (i) Following the appointment of Dr. Li as an executive Director, he has also been appointed as the chairman of the Strategy Committee;
- (ii) Dr. Taiyin Yang, an independent non-executive Director, has also been appointed as a member of the Strategy Committee; and
- (iii) Dr. Zhi Hong, an executive Director and the chairman of the Board, has ceased to be the chairman of the Strategy Committee.

APPOINTMENTS OF HEAD OF CHINA R&D AND GENERAL MANAGER, GREATER CHINA

The Board is pleased to announce the appointments of Dr. Qing Zhu (“**Dr. Zhu**”) as the Head of China Research and Development (“**R&D**”) of the Company with effect from October 1, 2022 in addition to her existing positions in the Company, and Mr. Rico Liang (“**Mr. Liang**”) as the Senior Vice President and General Manager, Greater China of the Company with effect from September 16, 2022.

Dr. Zhu has been appointed as the Head of China R&D with such appointment to take effect from October 1, 2022. She has been serving as the Senior Vice President (Head of Biopharmaceutical Research) of the Company since July 16, 2020, responsible for research and development of biotherapeutics. She was the Vice President (Head of Biopharmaceutical Research) of the Company from April 2, 2018 to July 15, 2020. Prior to joining the Group, Dr. Zhu held several positions in MedImmune, LLC (a subsidiary of AstraZeneca plc, which is a pharmaceutical company listed on London Stock Exchange in the United Kingdom (stock code: AZN) and New York Stock Exchange in the United States (stock code: AZN)) from August 2007 to March 2018 and her last position therein was director and head of virology group and she was responsible for research and development of antiviral programs. Before that, she was a scientist in Novartis Pharmaceuticals Corporation, a pharmaceutical company in the United States, and she was responsible for translational research from April 2006. She was a scientist in Chiron Corporation, a biotech company in the United States, and she was responsible for leading research projects from April 2004 to April 2006. She was a postdoctoral associate in Fox Chase Cancer Center, a research institute in the United States, and she completed postdoctoral training from May 2001 to April 2004. Dr. Zhu obtained her Bachelor of Science in Microbiology from ShanXi University in China in August 1989 and a Ph.D. in Molecular and Cell Biology Program from University of Maryland in the United States in July 2000.

Mr. Liang was promoted and has been appointed as the Senior Vice President and General Manager, Greater China of the Company with such appointment to take effect from September 16, 2022. He was the Vice President, Scientific and Medical Affairs of the Company from March 2021 to September 15, 2022 and the Head of Clinical Operation of the Company from January 2022 to September 15, 2022, responsible for leading external scientific engagements with key opinion leaders, medical associations and patient communities to facilitate trial execution and therapy launch preparation. Prior to joining the Group, Mr. Liang held several positions in Gilead China from February 2017 to February 2021, including the head of marketing, the head of human immunodeficiency virus sales and the executive marketing director, and he was responsible for commercial strategy design and implementation and leading marketing team to successfully deliver launches for innovative treatments. He was the senior marketing director of AbbVie Inc. China from May 2016 to February 2017, and he was responsible for building out hepatitis C virus marketing team and developing its portfolio strategy. He was the marketing director of Roche from July 2013 to May 2016, and he was responsible for leading several marketing programs to turn around Pegasys business. He held several positions in Novartis China from April 2004 to July 2013, including brand manager, senior global brand manager and medical advisor, during which he was responsible for Sebivo launch and medical strategies for diabetes pipeline and pain pipeline. He held several positions in Amgen Inc. from December 1996 to February 2002, including professional sales representative, senior professional sales representative and regional product manager. He was a medical practitioner at Beijing Fuxing Hospital from July 1991 to November 1996 working in internal medicine and intensive care unit. Mr. Liang obtained his Bachelor of Medicine from Capital University of Medical Science in China in July 1991 and a Master of Commerce in Marketing from Macquarie University in Australia in February 2004.

The Board would like to express its warm welcome to Dr. Zhu and Mr. Liang on their new appointments at the Company.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, September 2, 2022

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive Directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive Directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui, Mr. Gregg Huber Alton and Dr. Taiyin Yang as independent non-executive Directors.